Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17053328 | Role of PVT1 in the Diagnosis and Treatment of MYC-Driven Cancer | November 2020 | August 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 17066711 | HER2-TARGETING ANTIGEN BINDING MOLECULES COMPRISING 4-1BBL | October 2020 | December 2023 | Allow | 39 | 2 | 1 | No | No |
| 16982330 | COMBINATION OF ANTI-HGFR ANTIBODY AND HEGFR FOR THE TREATMENT OF A TUMOR AND/OR METASTASIS | September 2020 | July 2023 | Allow | 34 | 1 | 1 | No | No |
| 16979469 | COMBINATION TREATMENT OF CHEMORESISTANT CANCERS | September 2020 | September 2023 | Allow | 36 | 3 | 0 | No | No |
| 17010622 | BISPECIFIC EGFR/CD16 ANTIGEN-BINDING PROTEIN | September 2020 | July 2022 | Allow | 22 | 0 | 1 | No | No |
| 17005734 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | August 2020 | July 2022 | Abandon | 22 | 0 | 1 | No | No |
| 17004555 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AN INFLAMMATORY BOWEL DISEASE | August 2020 | May 2023 | Allow | 33 | 3 | 1 | Yes | No |
| 16975625 | DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES | August 2020 | December 2023 | Allow | 40 | 0 | 1 | No | No |
| 16997581 | B7-H4 ANTIBODY DOSING REGIMENS | August 2020 | December 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16968677 | ANTI-PD-1/ANTI-VEGF NATURAL ANTIBODY STRUCTURE LIKE HETERODIMERIC FORM BISPECIFIC ANTIBODY AND PREPARATION THEREOF | August 2020 | July 2023 | Allow | 36 | 1 | 1 | No | No |
| 16967288 | FIBROBLAST BINDING AGENTS AND USE THEREOF | August 2020 | September 2023 | Allow | 38 | 2 | 1 | No | No |
| 16944292 | ANTIBODIES BINDING TO GPRC5D | July 2020 | November 2022 | Abandon | 28 | 0 | 1 | No | No |
| 16964900 | L2A5 ANTIBODY OR FUNCTIONAL FRAGMENT THEREOF AGAINST TUMOUR ANTIGENS | July 2020 | February 2022 | Allow | 18 | 0 | 0 | No | No |
| 16928571 | HIV VACCINES AND METHODS OF MAKING AND USING | July 2020 | August 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16960297 | PD-L1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF | July 2020 | March 2022 | Allow | 20 | 0 | 1 | No | No |
| 16958536 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | June 2020 | September 2022 | Allow | 27 | 1 | 1 | No | No |
| 16954002 | CD19 VARIANTS | June 2020 | September 2023 | Allow | 39 | 3 | 1 | Yes | No |
| 16899512 | MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) COMPOSITIONS AND METHODS OF USE THEREOF | June 2020 | February 2024 | Abandon | 44 | 1 | 2 | No | No |
| 16898248 | USE OF A CEA CD3 BISPECIFIC ANTIBODY AND A PD-1 AXIS BINDING ANTAGONIST IN A DOSAGE REGIMEN TO TREAT CANCER | June 2020 | May 2024 | Abandon | 47 | 1 | 2 | No | No |
| 16769544 | ROBUST PANELS OF COLORECTAL CANCER BIOMARKERS | June 2020 | October 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16882362 | CANCER THERAPEUTIC METHODS UTILIZING OPCML FRAGMENT | May 2020 | August 2023 | Allow | 38 | 0 | 2 | No | No |
| 16881650 | ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME | May 2020 | January 2023 | Allow | 32 | 1 | 1 | No | No |
| 16878308 | Precision Medicine Method for Cancer Immunotherapy | May 2020 | March 2023 | Abandon | 34 | 1 | 1 | No | No |
| 15931726 | Combination Therapies With Bispecific Anti-EGFR/c-Met Antibodies and Third Generation EGFR Tyrosine Kinase Inhibitors | May 2020 | August 2023 | Allow | 39 | 4 | 1 | No | No |
| 16762088 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING CANCERS HAVING ELEVATED LEVELS OF PHOSPHORYLATED UBIQUITIN | May 2020 | May 2023 | Allow | 36 | 1 | 1 | No | No |
| 16761404 | MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS | May 2020 | May 2023 | Allow | 36 | 3 | 0 | No | No |
| 16855637 | COMBINATION THERAPY USING AN IL-20 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR | April 2020 | January 2023 | Allow | 33 | 1 | 1 | No | No |
| 16757178 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER | April 2020 | October 2023 | Abandon | 42 | 2 | 1 | No | No |
| 16850360 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | April 2020 | June 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16755686 | METHODS OF TREATING CANCERS | April 2020 | April 2022 | Allow | 24 | 0 | 1 | No | No |
| 16754068 | METHODS FOR TREATING LYMPHOMAS | April 2020 | May 2023 | Abandon | 37 | 2 | 2 | Yes | No |
| 16648792 | NOVEL BISPECIFIC CD3/CD19 POLYPEPTIDE COMPLEXES | March 2020 | April 2022 | Allow | 25 | 1 | 0 | No | No |
| 16648995 | NOVEL BISPECIFIC POLYPEPTIDE COMPLEXES | March 2020 | August 2023 | Allow | 41 | 3 | 1 | Yes | No |
| 16646875 | COMBINATION TREATMENT FOR CANCER | March 2020 | October 2023 | Abandon | 43 | 4 | 0 | No | No |
| 16811125 | USE OF MEGF11 AS DIAGNOSTIC AND PROGNOSTIC BIOMARKER AND THERAPEUTIC TARGET FOR TRIPLE NEGATIVE BREAST CANCER | March 2020 | March 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16640617 | METHODS FOR DETECTING Na/K-ATPASE-MEDIATED SRC SIGNALING FOR DIAGNOSIS AND PROGNOSIS OF CANCER | February 2020 | June 2023 | Allow | 39 | 2 | 1 | No | No |
| 16792115 | ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND THERAPY | February 2020 | April 2022 | Allow | 26 | 0 | 1 | No | No |
| 16751144 | CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS | January 2020 | November 2022 | Allow | 33 | 1 | 1 | No | No |
| 16633389 | METHOD FOR PREDICTING THE RESPONSE OF NON-SMALL-CELL LUNG CARCINOMA PATIENTS TO A MEDICAMENT | January 2020 | July 2023 | Allow | 42 | 2 | 1 | No | No |
| 16737950 | PROSTATE NEOANTIGENS AND THEIR USES | January 2020 | May 2023 | Allow | 40 | 1 | 1 | No | No |
| 16732369 | ANTIHUMAN PCSK9 MONOCLONAL ANTIBODY AND APPLICATION THEREOF | January 2020 | December 2021 | Allow | 24 | 0 | 1 | No | No |
| 16626768 | METHODS OF TREATING CISPLATIN-RESISTANT CANCER WITH COMBINED CISPLATIN AND LCK INHIBITOR | December 2019 | May 2023 | Allow | 41 | 3 | 1 | No | No |
| 16625239 | PERSONALIZED VACCINE | December 2019 | January 2024 | Allow | 49 | 3 | 0 | Yes | No |
| 16721108 | COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS | December 2019 | June 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16624408 | Recombinant Bispecific Antibodies to PD-L1 and CTLA-4 | December 2019 | April 2022 | Allow | 28 | 1 | 1 | No | No |
| 16719154 | USE OF IL-1BETA BINDING ANTIBODIES | December 2019 | June 2022 | Abandon | 29 | 1 | 0 | No | No |
| 16719273 | BISPECIFIC ANTI-MUC16 X ANTI-CD28 ANTIBODIES AND USES THEREOF | December 2019 | May 2022 | Allow | 29 | 1 | 1 | No | No |
| 16719015 | BISPECIFIC ANTI-CD28 X ANTI-CD22 ANTIBODIES AND USES THEREOF | December 2019 | March 2022 | Allow | 27 | 1 | 1 | No | No |
| 16719220 | CD70 COMBINATION THERAPY | December 2019 | March 2023 | Allow | 39 | 3 | 1 | No | No |
| 16715621 | TWIN IMMUNE CELL ENGAGER | December 2019 | March 2023 | Allow | 39 | 2 | 1 | No | No |
| 16710938 | BLOOD-BASED TUMOR MUTATION BURDEN PREDICTS OVERALL SURVIVAL IN NSCLC | December 2019 | March 2023 | Abandon | 39 | 2 | 1 | No | No |
| 16704679 | METHODS AND IMMUNOGENIC COMPOSITIONS RELATING TO HER2 WITH SELECTIVE SEQUENCE MODIFICATIONS | December 2019 | February 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16698203 | METHOD FOR DETECTION OF TRAUMATIC BRAIN INJURY | November 2019 | September 2023 | Allow | 46 | 2 | 1 | No | No |
| 16616146 | ANTI-ANGIOGENIC ADENOVIRUS | November 2019 | August 2024 | Abandon | 57 | 4 | 1 | No | No |
| 16693060 | TYPE II ANTI-CD20 ANTIBODY AND ANTI-CD20/CD3 BISPECIFIC ANTIBODY FOR TREATMENT OF CANCER | November 2019 | October 2023 | Abandon | 46 | 4 | 1 | No | No |
| 16693056 | METHODS OF TREATING CANCER WITH COMBINATIONS OF ANTI-CD3 ANTIBODY AND GLUCOCORTICOID | November 2019 | May 2024 | Abandon | 53 | 5 | 1 | Yes | No |
| 16615231 | PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | November 2019 | March 2024 | Abandon | 52 | 5 | 1 | No | No |
| 16605748 | THERAPEUTIC GENOME EDITING IN WISKOTT-ALDRICH SYNDROME AND X-LINKED THROMBOCYTOPENIA | October 2019 | January 2023 | Allow | 39 | 1 | 1 | No | No |
| 16604341 | ANTI-EGFR/HIGH AFFINITY NK-CELLS COMPOSITIONS AND METHODS FOR CHORDOMA TREATMENT | October 2019 | July 2022 | Abandon | 34 | 1 | 1 | Yes | No |
| 16587405 | EFFICIENT CRISPR/HDR-MEDIATED KNOCK-IN SYSTEM AND METHOD OF USE | September 2019 | November 2022 | Allow | 37 | 1 | 1 | No | No |
| 16491647 | Compositions and Methods For Treating Cancer with Anti-Renalase antibodies and Anti-PD1 antibodies | September 2019 | January 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16348696 | IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS | May 2019 | November 2022 | Abandon | 42 | 1 | 1 | No | No |
| 16345210 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | April 2019 | June 2022 | Abandon | 37 | 1 | 1 | No | No |
| 16098817 | BIOMARKERS SIGNATURE DISCOVERY AND SELECTION | November 2018 | November 2022 | Abandon | 48 | 0 | 1 | No | No |
| 16174769 | ALGORITHMS FOR DISEASE DIAGNOSTICS | October 2018 | May 2024 | Abandon | 60 | 2 | 0 | No | No |
| 15768235 | ANTI-ROR1 ANTIBODIES | April 2018 | July 2023 | Allow | 60 | 6 | 1 | No | No |
| 15764870 | BINDING MOLECULES WITH MODIFIED J-CHAIN | March 2018 | January 2023 | Allow | 58 | 5 | 1 | No | No |
| 14489182 | COMPOSITIONS OF A CARBOHYDRATE VACCINE FOR INDUCING IMMUNE RESPONSES AND USES THEREOF IN CANCER TREATMENT | September 2014 | January 2024 | Allow | 60 | 12 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ALSOMAIRY, SARAH ABDOALATIF works in Art Unit 1642 and has examined 68 patent applications in our dataset. With an allowance rate of 61.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner ALSOMAIRY, SARAH ABDOALATIF's allowance rate of 61.8% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALSOMAIRY, SARAH ABDOALATIF receive 1.87 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ALSOMAIRY, SARAH ABDOALATIF is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +9.7% benefit to allowance rate for applications examined by ALSOMAIRY, SARAH ABDOALATIF. This interview benefit is in the 42% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 25.8% of applications are subsequently allowed. This success rate is in the 44% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 14.3% are granted (fully or in part). This grant rate is in the 8% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.5% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.